A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
Prostate cancer is often called a “silent killer,” and for good reason. You don’t get a big set of warnings, and for a lot of ...
Prostate-specific antigen (PSA) is a uniquely valid tumor marker for prostate cancer screening and early detection. 1 The widespread use of serum PSA testing for early prostate cancer detection has ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader ...
Prostate cancer is absurdly common, but many men are mum about it. Joe Biden’s diagnosis has focused public attention on it. Good morning. I’m Mark Shanahan, guest-writing Starting Point to tell you ...
Charlie Wilson, Jean Fogelberg and Rosey Grier Join “Advance on Washington” to Improve Treatments, Reduce Overtreatment WASHINGTON--(BUSINESS WIRE)-- With $3 billion spent on the over-treatment of ...
Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results